中国国际医疗器械设计与制造技术展览会(Medtec China)2021


2022年8月31-9月2日 | 上海世博展览馆1&2号馆

Perfecting the Future of Data-Driven Healthcare


Data-driven patient care is undoubtedly the future of the healthcare field. Automation opens the door to improved efficiencies, more personalized care, and improved profitability, but in healthcare, the implementation and advancement of these technologies are not without challenges unique to medicine.

Data-driven patient care is undoubtedly the future of the healthcare field. Automation opens the door to improved efficiencies, more personalized care, and improved profitability, but in healthcare, the implementation and advancement of these technologies are not without challenges unique to medicine.

Healthcare data is not only highly variable and complex but is extremely sensitive. Given the regulated nature of healthcare data and patient information, mistakes can compromise HIPAA compliance, and even more severe, mismanaged data can potentially result in life or death results.

However, the promise of these technologies is enormous. A few years ago, John Hopkins conducted a study establishing medical error as the third-leading cause of death in the United States. The maturation of AI and ML tools will help doctors identify complications before their life or death and ultimately improve patient outcomes.

Patrick Bangert, VP of AI at Samsung SDSA, is set to address the key risks and opportunities that automation technologies pose in the healthcare space in a keynote panel at the upcoming BIOMEDevice Silicon Valley Smart Event, titled “The Three Magic Words for Healthcare - Artificial Intelligence, Big Data & Edge Computing.” The premiere exhibition, slated to take place December 8 and 9 at the San Jose McEnery Convention Center, is strategically designed to connect biotech and medtech engineers and cutting-edge companies and provide world-class education both in-person and online.

With the event on the near horizon, I had the distinct pleasure of sitting down with Patrick and discussing the keynote panel and what attendees can look forward to learning.

AI and ML capabilities are driving the smarter delivery of more efficient and precise products. What notable trends are emerging as a result of integrating AI/ML capabilities with healthcare?
Bangert: Automation is the primary benefit of AI in any industry. AI frees up doctors and other healthcare professionals to focus on the patient where momentarily they are spending 75% of their time analyzing data and doing paperwork. Patients have to wait 4-6 weeks, unaware of the results of a biopsy. If those are available instantly, the treatment can begin sooner, leading to better outcomes. The most significant benefit will be felt in those regions that don’t have A-rated facilities. On average, 30% of human diagnoses are mistaken, while AI can be accurate to over 99%. AI can democratize healthcare worldwide.

Ongoing technological advances open the door for medical breakthroughs but also incite new obstacles. Could you speak to these challenges? Bangert: Regulation is a major obstacle, particularly because the regulation is different in every country. Trust is a worldwide obstacle to AI adoption in many areas, and we have much work ahead to have the population at large trust an automated system with their health. For the technology sector, the main obstacle, however, is quality data. The data must be acquired and annotated by human experts, which is the main cost of AI. We at Samsung SDS are reducing this work by 90% with AI automation.

How do you see today’s data-driven approach to research and device development impacting healthcare delivery in the future?
Bangert: This will speed up the industry by leaps and bounds and reduce research costs significantly. We can expect to see progress at a faster pace and also updates in hospitals faster than before.

You are speaking on a keynote panel with three peers at BIOMEDevice Silicon Valley. What can attendees look forward to learning?
Bangert: A key frontier for AI is medical devices. The frontier for medical devices is AI. The industry has been improving medical devices little by little over many years. There is little breakthrough or game-changing innovation. AI offers a bold new vision where the medical device is the first step as a sensor to the world, but it is the analysis of the acquired data that presents the value – both to the industry as well as the patient.

What excites you most about engaging with your community in person this December?
Bangert: Meeting them in person, learning about new developments, and sharing ideas about how AI can help drive innovation and make devices as well as outcomes better.

Secure a pass here to tune into the keynote pane and engage with more than 200 suppliers advancing the integration of advanced technologies in healthcare. Access the online platform that is open today and begin earning points for the chance to win cash and high-tech prizes. The more education you tune into, the more points you earn!

Article source: Qmed and MD+DI




















2015年,制造装备公司楚天科技(行情300358,诊股)(300358,SZ)表示正在研发医药机器人和医疗机器人,一年后,首台医药无菌生产智能机器人下线,步入医药装备4.0时代;2017年11月,科大讯飞(行情002230,诊股)(002230,SZ)研发的医疗机器人“智医助理”通过临床执业医师综合笔试,目前已进入合肥基层卫生中心,辅助全科医生进行诊疗;2017年,埃斯顿(行情002747,诊股)(002747,SZ)收购美国Barrett 30%股权,全面进军康复医疗机器人市场,并计划与Barrett共同出资在中国境内成立一家新的合公司。


国产机器人拥有成本优势 在多家企业布局的背后,是医疗机器人巨大的市场潜力。普华永道中国发布的《医疗机器人宏观应用趋势与研究方向》显示,2014年,全球医疗机器人的市场价值是26亿美元,到2020年预计会达到76亿美元。